GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (NAS:SCPH) » Definitions » EBIT per Share

SCPH (scPharmaceuticals) EBIT per Share : $-1.71 (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is scPharmaceuticals EBIT per Share?

scPharmaceuticals's EBIT per Share for the three months ended in Sep. 2024 was $-0.71. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.71.

During the past 3 years, the average EBIT per Share Growth Rate was -5.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for scPharmaceuticals's EBIT per Share or its related term are showing as below:

SCPH' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -18.2   Med: 3.45   Max: 46.4
Current: -5.7

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of scPharmaceuticals was 46.40% per year. The lowest was -18.20% per year. And the median was 3.45% per year.

SCPH's 3-Year EBIT Growth Rate is ranked worse than
60.91% of 1256 companies
in the Biotechnology industry
Industry Median: 2.8 vs SCPH: -5.70

scPharmaceuticals's EBIT for the three months ended in Sep. 2024 was $-33.26 Mil.


scPharmaceuticals EBIT per Share Historical Data

The historical data trend for scPharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals EBIT per Share Chart

scPharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial Premium Member Only -1.68 -1.21 -0.93 -1.18 -1.21

scPharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.35 -0.30 -0.31 -0.38 -0.71

scPharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

scPharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-46.687/38.514
=-1.21

scPharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

EBIT per Share(Q: Sep. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-33.255/46.558
=-0.71

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


scPharmaceuticals  (NAS:SCPH) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


scPharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


scPharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
25 Mall Road, Suite 203, Burlington, MA, USA, 01803
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
Executives
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Iv, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jack A. Khattar director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
John H Tucker director, officer: President and CEO INDEVUS PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, LEXINGTON MA 02421
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
William Tober Abraham director C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310, BURLINGTON MA 01803
Sara Bonstein director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Andrew J. Schwab 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc other: See Remarks 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p. other: See Remarks 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rachael Nokes officer: See Remarks C/O SCPHARMACEUITCALS, INC., 2400 DISTRICT AVENUE, BURLINGTON MA 01803